{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:04:30Z","timestamp":1761512670629,"version":"3.37.3"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1124\/jpet.109.150540","type":"journal-article","created":{"date-parts":[[2009,4,9]],"date-time":"2009-04-09T01:48:58Z","timestamp":1239241738000},"page":"236-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine"],"prefix":"10.1016","volume":"330","author":[{"given":"Katherine L.","family":"Nicholson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Balster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystyna","family":"Golembiowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Kowalska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph P.","family":"Tizzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phil","family":"Skolnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony S.","family":"Basile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.109.150540_bib1","doi-asserted-by":"crossref","unstructured":"Baker LE, Riddle EE, Saunders RB, and Appel JB (1993) The role of monoamine uptake in the discriminative stimulus effects of cocaine and related compounds. Behav Pharmacol 4: 69-79.","DOI":"10.1097\/00008877-199302000-00008"},{"key":"10.1124\/jpet.109.150540_bib2","doi-asserted-by":"crossref","unstructured":"Balster RL, Carroll FI, Graham JH, Mansbach RS, Rahman MA, Philip A, Lewin AH, and Showalter VM (1991) Potent substituted-3-beta-phenyltropane analogs of cocaine have cocaine-like discriminative stimulus effects. Drug Alcohol Depend 29: 145-151.","DOI":"10.1016\/0376-8716(91)90043-X"},{"key":"10.1124\/jpet.109.150540_bib3","doi-asserted-by":"crossref","unstructured":"Barkin RL and Barkin S (2005) The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy. Am J Ther 12: 431-438.","DOI":"10.1097\/01.mjt.0000162011.58990.94"},{"key":"10.1124\/jpet.109.150540_bib4","doi-asserted-by":"crossref","unstructured":"Basile AS, Janowsky A, Golembiowska K, Kowalska M, Tam E, Benveniste M, Popik P, Nikiforuk A, Krawczyk M, Nowak G, et al. (2007) Characterization of the antinociceptive actions of bicifadine in models of acute, persistent and chronic pain. J Pharmacol Exp Ther 321: 1208-1225.","DOI":"10.1124\/jpet.106.116483"},{"key":"10.1124\/jpet.109.150540_bib5","doi-asserted-by":"crossref","unstructured":"Bergman J, Madras BK, Johnson SE, and Spealman RD (1989) Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther 251: 150-155.","DOI":"10.1016\/S0022-3565(25)20689-9"},{"key":"10.1124\/jpet.109.150540_bib6","doi-asserted-by":"crossref","unstructured":"Broadbent J, Michael EK, Riddle EE, and Apple JB (1991) Involvement of dopamine uptake in the discriminative stimulus effects of cocaine. Behav Pharmacol 2: 187-197.","DOI":"10.1097\/00008877-199106000-00002"},{"key":"10.1124\/jpet.109.150540_bib7","doi-asserted-by":"crossref","unstructured":"Carroll ME, Lac ST, Asencio M, and Kragh R (1990) Fluoxetine reduces intravenous cocaine self-administration in rats. Pharmacol Biochem Behav 35: 237-244.","DOI":"10.1016\/0091-3057(90)90232-7"},{"key":"10.1124\/jpet.109.150540_bib8","doi-asserted-by":"crossref","unstructured":"Czoty PW, Ginsburg BC, and Howell LL (2002) Serotonergic attenuation of the reinforcing and neurochemical effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 300: 831-837.","DOI":"10.1124\/jpet.300.3.831"},{"key":"10.1124\/jpet.109.150540_bib9","doi-asserted-by":"crossref","unstructured":"Desai RI, Kopajtic TA, Koffarnus M, Newman AH, and Katz JL (2005) Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci 25: 1889-1893.","DOI":"10.1523\/JNEUROSCI.4778-04.2005"},{"key":"10.1124\/jpet.109.150540_bib10","doi-asserted-by":"crossref","unstructured":"Dwoskin LP, Rauhut AS, King-Pospisil KA, and Bardo MT (2006) Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 12: 178-207.","DOI":"10.1111\/j.1527-3458.2006.00178.x"},{"key":"10.1124\/jpet.109.150540_bib11","doi-asserted-by":"crossref","unstructured":"Fink KB and G\u00f6thert M (2007) 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 59: 360-417.","DOI":"10.1124\/pr.59.07103"},{"key":"10.1124\/jpet.109.150540_bib12","doi-asserted-by":"crossref","unstructured":"Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, and Hanson GR (2007) New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47: 681-698.","DOI":"10.1146\/annurev.pharmtox.47.120505.105140"},{"key":"10.1124\/jpet.109.150540_bib13","doi-asserted-by":"crossref","unstructured":"Gasior M, Bergman J, Kallman MJ, and Paronis CA (2005) Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys. Neuropsychopharmacology 30: 758-764.","DOI":"10.1038\/sj.npp.1300593"},{"key":"10.1124\/jpet.109.150540_bib14","doi-asserted-by":"crossref","unstructured":"Gold LH and Balster RL (1996) Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berl) 126: 286-292.","DOI":"10.1007\/BF02247379"},{"key":"10.1124\/jpet.109.150540_bib15","doi-asserted-by":"crossref","unstructured":"Hnasko TS, Sotak BN, and Palmiter RD (2007) Cocaine-conditioned place preference by dopamine-deficient mice is mediated by serotonin. J Neurosci 27: 12484-12488.","DOI":"10.1523\/JNEUROSCI.3133-07.2007"},{"key":"10.1124\/jpet.109.150540_bib16","doi-asserted-by":"crossref","unstructured":"Howell LL and Byrd LD (1995) Serotonergic modulation of the behavioral effects of cocaine in the squirrel monkey. J Pharmacol Exp Ther 275: 1551-1559.","DOI":"10.1016\/S0022-3565(25)12217-9"},{"key":"10.1124\/jpet.109.150540_bib17","doi-asserted-by":"crossref","unstructured":"Howell LL, Carroll FI, Votaw JR, Goodman MM, and Kimmel HL (2007) Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther 320: 757-765.","DOI":"10.1124\/jpet.106.108324"},{"key":"10.1124\/jpet.109.150540_bib18","unstructured":"Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC."},{"key":"10.1124\/jpet.109.150540_bib19","doi-asserted-by":"crossref","unstructured":"Katz JL, Izenwasser S, and Terry P (2000) Relationships among dopamine transporter affinities and cocaine-like discriminative-stimulus effects. Psychopharmacology (Berl) 148: 90-98.","DOI":"10.1007\/s002130050029"},{"key":"10.1124\/jpet.109.150540_bib20","doi-asserted-by":"crossref","unstructured":"Koob GF (1992) Neural mechanisms of drug reinforcement. Ann N Y Acad Sci 654: 171-191.","DOI":"10.1111\/j.1749-6632.1992.tb25966.x"},{"key":"10.1124\/jpet.109.150540_bib21","doi-asserted-by":"crossref","unstructured":"Kozikowski AP, Johnson KM, Deschaux O, Bandyopadhyay BC, Araldi GL, Carmona G, Munzar P, Smith MP, Balster RL, Beardsley PM, et al. (2003) Mixed cocaine agonist\/antagonist properties of (+)-methyl 4\u03b2-(chlorophenyl)-1-methylpiperidine-3\u03b1-carboxylate, a piperidine-based analog of cocaine. J Pharmacol Exp Ther 305: 143-150.","DOI":"10.1124\/jpet.102.046318"},{"key":"10.1124\/jpet.109.150540_bib22","doi-asserted-by":"crossref","unstructured":"Kratochvil CJ, Vaughan BS, Harrington MJ, and Burke WJ (2003) Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit\/hyperactivity disorder. Expert Opin Pharmacother 4: 1165-1174.","DOI":"10.1517\/eoph.4.7.1165.21068"},{"key":"10.1124\/jpet.109.150540_bib23","doi-asserted-by":"crossref","unstructured":"Krieter PA, Gohdes M, Musick TJ, Duncanson FP, and Bridson WE (2008) Pharmacokinetics, disposition, and metabolism of bicifadine in humans. Drug Metab Dispos 36: 252-259.","DOI":"10.1124\/dmd.107.017871"},{"key":"10.1124\/jpet.109.150540_bib24","doi-asserted-by":"crossref","unstructured":"Lamb RJ and Griffiths RR (1990) Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine. Psychopharmacology (Berl) 102: 183-190.","DOI":"10.1007\/BF02245920"},{"key":"10.1124\/jpet.109.150540_bib25","doi-asserted-by":"crossref","unstructured":"Lanteri C, Salomon L, Torrens Y, Glowinski J, and Tassin JP (2008) Drugs of abuse specifically sensitize noradrenergic and serotonergic neurons via a nondopaminergic mechanism. Neuropsychopharmacology 33: 1724-1734.","DOI":"10.1038\/sj.npp.1301548"},{"key":"10.1124\/jpet.109.150540_bib26","doi-asserted-by":"crossref","unstructured":"Lile JA, Morgan D, Birmingham AM, Wang Z, Woolverton WL, Davies HM, and Nader MA (2002) The reinforcing efficacy of the dopamine reuptake inhibitor 2beta-propanoyl-3beta-(4-tolyl)-tropane (PTT) as measured by a progressive-ratio schedule and a choice procedure in rhesus monkeys. J Pharmacol Exp Ther 303: 640-648.","DOI":"10.1124\/jpet.102.039180"},{"key":"10.1124\/jpet.109.150540_bib27","doi-asserted-by":"crossref","unstructured":"Lile JA, Wang Z, Woolverton WL, France JE, Gregg TC, Davies HM, and Nader MA (2003) The reinforcing efficacy of psychostimulants in rhesus monkeys: the role of pharmacokinetics and pharmacodynamics. J Pharmacol Exp Ther 307: 356-366.","DOI":"10.1124\/jpet.103.049825"},{"key":"10.1124\/jpet.109.150540_bib28","doi-asserted-by":"crossref","unstructured":"Loland CJ, Desai RI, Zou MF, Cao J, Grundt P, Gerstbrein K, Sitte HH, Newman AH, Katz JL, and Gether U (2008) Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol 73: 813-823.","DOI":"10.1124\/mol.107.039800"},{"key":"10.1124\/jpet.109.150540_bib29","doi-asserted-by":"crossref","unstructured":"McMillen BA, Shank JE, Jordan KB, Williams HL, and Basile AS (2007) The effect of DOV 102,677 on the volitional consumption of ethanol by the Myer\u2019s high ethanol preferring rats. Alcohol Clin Exp Res 31: 1866-1871.","DOI":"10.1111\/j.1530-0277.2007.00513.x"},{"key":"10.1124\/jpet.109.150540_bib30","doi-asserted-by":"crossref","unstructured":"Reith ME, Li MY, and Yan QS (1997) Extracellular dopamine, norepinephrine, and serotonin in the ventral tegmental area and nucleus accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers. Psychopharmacology (Berl) 134: 309-317.","DOI":"10.1007\/s002130050454"},{"key":"10.1124\/jpet.109.150540_bib31","doi-asserted-by":"crossref","unstructured":"Riddle EL, Fleckenstein AE, and Hanson GR (2005) Role of monoamine transporters in mediating psychostimulant effects. AAPS J 7: E847-E851.","DOI":"10.1208\/aapsj070481"},{"key":"10.1124\/jpet.109.150540_bib32","doi-asserted-by":"crossref","unstructured":"Skolnick P and Basile AS (2007) Triple reuptake inhibitors (\u201cbroad spectrum\u201d antidepressants). CNS Neurol Disord Drug Targets 6: 141-149.","DOI":"10.2174\/187152707780363285"},{"key":"10.1124\/jpet.109.150540_bib33","doi-asserted-by":"crossref","unstructured":"Tella SR and Goldberg SR (2001) Subtle differences in the discriminative stimulus effects of cocaine and GBR-12909. Prog Neuropsychopharmacol Biol Psychiatry 25: 639-656.","DOI":"10.1016\/S0278-5846(00)00180-9"},{"key":"10.1124\/jpet.109.150540_bib34","doi-asserted-by":"crossref","unstructured":"Tella SR, Ladenheim B, and Cadet JL (1997) Differential regulation of dopamine transporter after chronic self-administration of bupropion and nomifensine. J Pharmacol Exp Ther 281: 508-513.","DOI":"10.1016\/S0022-3565(24)36624-8"},{"key":"10.1124\/jpet.109.150540_bib35","doi-asserted-by":"crossref","unstructured":"Tizzano JP, Stribling DS, Perez-Tilve D, Strack A, Frassetto A, Chen RZ, Fong TM, Shearman L, Krieter PA, Tsch\u00f6p MH, et al. (2008) The triple uptake inhibitor DOV 21947 reduces body weight and plasma triglycerides in rodent models of diet-induced obesity. J Pharmacol Exp Ther 324: 1111-1126.","DOI":"10.1124\/jpet.107.133132"},{"key":"10.1124\/jpet.109.150540_bib36","doi-asserted-by":"crossref","unstructured":"Vaswani M, Linda FK, and Ramesh S (2003) Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27: 85-102.","DOI":"10.1016\/S0278-5846(02)00338-X"},{"key":"10.1124\/jpet.109.150540_bib37","doi-asserted-by":"crossref","unstructured":"Venton BJ, Seipel AT, Phillips PE, Wetsel WC, Gitler D, Greengard P, Augustine GJ, and Wightman RM (2006) Cocaine increases dopamine release by mobilization of a synapsin-dependent reserve pool. J Neurosci 26: 3206-3209.","DOI":"10.1523\/JNEUROSCI.4901-04.2006"},{"key":"10.1124\/jpet.109.150540_bib38","doi-asserted-by":"crossref","unstructured":"Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, and Woolverton WL (2005) Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther 313: 848-854.","DOI":"10.1124\/jpet.104.080101"},{"key":"10.1124\/jpet.109.150540_bib39","doi-asserted-by":"crossref","unstructured":"Wise RA (2002) Brain reward circuitry: insights from unseen incentives. Neuron 36: 229-240.","DOI":"10.1016\/S0896-6273(02)00965-0"},{"key":"10.1124\/jpet.109.150540_bib40","doi-asserted-by":"crossref","unstructured":"Woolverton WL and Johnson KM (1992) Neurobiology of cocaine abuse. Trends Pharmacol Sci 13: 193-200.","DOI":"10.1016\/0165-6147(92)90063-C"},{"key":"10.1124\/jpet.109.150540_bib41","unstructured":"Young AM and Herling S (1986) Drugs as reinforcers: studies in laboratory animals, in Behavioral Analysis of Drug Dependence (Goldberg SR and Stolerman IP eds) pp 9-67, Academic Press, Orlando."}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652438512X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235652438512X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.109.150540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T01:32:53Z","timestamp":1740015173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235652438512X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S002235652438512X"],"URL":"https:\/\/doi.org\/10.1124\/jpet.109.150540","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.109.150540","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2009 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}